Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Pico Rivera, California Clinical Trials

A listing of Pico Rivera, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (42) clinical trials

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Phase

5.77 miles

Learn More »

Study of Acalabrutinib Alone or in Combination With Rituximab in Indolent B-cell Non-Hodgkin Lymphoma

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent B cell Non-Hodgkin Lymphoma - Marginal Zone Lymphoma

Phase

6.51 miles

Learn More »

A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC)

This phase 1/2 study will evaluate the safety, pharmacokinetics, and anti-tumor activity of oral EGFR/HER2 Inhibitor TAK-788 in participants with NSCLC and anti-tumor activity of TAK-788 in participants with solid tumors other than NSCLC with EGFR or HER2 mutations. The trial will be conducted in three parts: a dose escalation ...

Phase

6.57 miles

Learn More »

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

The dose-escalation Part A of this study will involve patients with advanced solid malignancies refractory to standard therapy or for which no standard of care regimen currently exists. Approximately 30 evaluable patients per treatment arm (A1 or A2) will be enrolled. A3 will test viability of alternate dosing schedule for ...

Phase

6.57 miles

Learn More »

Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2)

This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal GEN-1 plus NACT compared to NACT alone.

Phase

6.57 miles

Learn More »

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

This is a Phase 1/2, open-label, non-comparative, multicenter, multi-arm study of the Wilms Tumor-1 (WT1)-targeting multivalent heteroclitic peptide immunotherapeutic vaccine galinpepimut-S in combination with the programmed death-1 (PD1) inhibitor pembrolizumab in patients with selected advanced cancers. This study will assess the efficacy and safety of galinpepimut-S and pembrolizumab and investigate ...

Phase

6.57 miles

Learn More »

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

This is a modular, phase I, 2 part, open-label, multicentre study of AZD6738, administered orally, in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced/metastatic solid malignancies. The study design allows an escalation of the dose of AZD6738 in combination with the standard dose and schedule ...

Phase

7.84 miles

Learn More »

Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

In this multi-institution phase I/II trial, the investigators have chosen paclitaxel and carboplatin using a schedule and doses identical to those used in the CROSS trial. Following a run-in with nivolumab alone at 240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will ...

Phase

7.84 miles

Learn More »

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)

A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic G/GEJ cancer (hereafter referred to as gastric cancer). Two cohorts will be enrolled in parallel in this study: the ...

Phase

7.84 miles

Learn More »

Dabrafenib Trametinib and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD), toxicity, and safety profile of navitoclax when given in combination with dabrafenib and trametinib in patients with BRAF-mutant solid tumors. (Phase I) II. To estimate the complete response (CR) rate in patients with BRAF-mutant melanoma treated with dabrafenib, trametinib, and ...

Phase

7.84 miles

Learn More »